Aims Thrombolytic therapy restores coronary patency in patients with acute myocardial infarction, although normal perfusion (TIMI 3 flow) is not achieved in all patients. In an attempt to improve TIMI 3 flow, a combination of full-dose streptokinase, aspirin and escalating dosages of a platelet glycoprotein IIb/IIIa receptor blocker, eptifibatide, vs placebo were tested.
Introduction
Coronary occlusion in acute myocardial infarction is caused by intracoronary platelet aggregation and fibrin formation which together forms an intracoronary thrombus. Fibrin can be dissolved by fibrinolytic therapy, while the final common pathway of platelet aggregation can be blocked with platelet glycoprotein (GP) IIb/IIIa receptor inhibitors [1, 2] . Various agents have been tested in percutaneous coronary intervention, unstable angina and myocardial infarction [3] [4] [5] [6] [7] [8] [9] [10] . Eptifibatide is a synthetic GP IIb/IIIa platelet receptor antagonist providing high levels of receptor blockade in vitro and in vivo. Such platelet receptor blockade may enhance thrombolytic therapy and improve clot resolution [11] [12] [13] [14] . Indeed, a combination of eptifibatide with full-dose alteplase and heparin showed an improve-ment in TIMI 3 flow rates within 90 min of 39% with placebo to 66% in eptifibatide-treated patients [15] . Streptokinase is used widely for the treatment of acute myocardial infarction. Since this therapy yields a 32-56% TIMI 3 flow at 90 min [16, 17] , this drug may be improved by the addition of a platelet GP IIb/IIIa receptor inhibitor. Therefore combined therapy with streptokinase and eptifibatide was tested, focusing on early (90 min), as well as late (7 days) perfusion of the infarct-related artery, and on the safety of various dose combinations.
Methods

Patients
Patients were enrolled if they had evolving myocardial infarction and onset of chest pain within 6 h, STelevation of 0·1 mV in two or more standard leads or 0·2 mV in two or more precordial leads. Patients over 75 years of age had to weigh more than 50 kg, to avoid the excessive risk of intracranial haemorrhage [18] . Exclusion criteria were previous cerebrovascular disease, previous coronary artery bypass graft operation (CABG), current anticoagulant therapy, as well as recent gastro-intestinal or urinary tract bleeding, severe trauma or major surgery; known thrombocytopenia, known liver and kidney function abnormalities; and suspected streptokinase intolerance. The lower age limit was 18 years.
Witnessed oral informed consent was requested, confirmed by written consent at a later stage during hospitalization. The medical ethics committees of all participating hospitals gave approval for this trial.
Treatment
Treatment consisted of an aspirin loading dose of 250-500 mg, continued with at least 80 mg daily, and 1·5 million units of streptokinase given intravenously in 60 min. Eptifibatide or placebo, randomized 2:1, was administered within 10 min but in no case later than 30 min after the start of streptokinase with a bolus dose of 180 g . kg 1 and escalating dosages of a 72 h continuous infusion: 0·75, 1·33 and 2·00 g . kg 1 . min 1 . The lowest dosage of eptifibatide was similar to the optimal level in the comparable dose-finding IMPACT-AMI trial of alteplase and eptifibatide [15] . The highest dose corresponded to the regimen tested in PUR-SUIT [19] . Following recommendations by the European Society of Cardiology [20] , heparin was not given in the current trial, which is in contrast to IMPACT-AMI [15] . Other medication was left at the discretion of the investigator. Warfarin, abciximab and intravenous dextran were not to be combined with the study medication.
End-point analysis
TIMI criteria were used to assess bleeding during hospitalization [21] . Major bleeding was defined as intracranial haemorrhage or an Hb decrease of at least 5 g . dl 1 (3·1 mmol . l 1 ) or an Ht decrease of 15% or more. Minor bleeding was described as spontaneous gross haematuria or haematemesis or an Hb decrease between 4 and 5 g . dl 1 (2·5 to 3·1 mmol . l 1 ) or an Ht decrease of 10% to 15%. Angiography was performed after 90 min and repeated after approximately 7 days. TIMI flow grades were evaluated by the investigators and by an independent core laboratory (Cardialysis, Rotterdam, The Netherlands). TIMI 0 represents absence of flow antegrade of the occlusion. TIMI 1 denotes penetration of the contrast agent without perfusion and failing to opacify the entire coronary bed distal to the occlusion. TIMI 2 shows partial perfusion with a slower rate of entry or clearance of the coronary bed than in other comparable areas. TIMI 3 flow is defined by complete perfusion with antegrade flow proximal to the obstruction and rapid clearance from an uninvolved bed in the same or opposite coronary artery [17] . At 7 days coronary angiography was repeated and ventriculography was performed to assess left ventricular ejection fraction, except in patients who underwent rescue percutaneous transluminal coronary angioplasty (PTCA) or bypass surgery. TIMI flow grades of both angiograms were compared to determine re-occlusion.
ST-segment resolution was calculated from 12 lead ECGs, recorded immediately before and 3 h after start of therapy. Resolution was expressed as complete (over 70%), partial (30 to 70%) and no ST-segment resolution (less than 30%) [22, 23] . After approximately 42 evaluable patients in each dose, the Safety Review Committee assessed safety and efficacy and decided on possible dosage escalation.
Results
In 1996 and 1997, 181 patients were enrolled in 24 hospitals in Germany and the Netherlands. The highest dose group was discontinued after enrollment of 30 patients because of excess bleeding complications. Baseline characteristics were similar among the different treatment groups (Table 1) . Two patients in the placebo group, one patient in the lowest dose group and two patients in the highest dose group did not receive full dose streptokinase. In the dose group one patient was withdrawn by a treating physician. These patients were retained in the analyses.
The mean duration of the eptifibatide or placebo infusions was between 63 and 67 h (standard deviation 18 to 21 h). The study drug was discontinued because of bleeding complications in seven eptifibatide-treated patients and because of loss of haemoglobin without manifest bleeding in two other patients (in the median and high dose groups). In another 23 patients, the study was prematurely discontinued due to various causes (cardiac events, nursing errors, incompatible co-medication), not different among treatment groups. In total, 15% of patients discontinued in the placebo
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group, and 21%, 18% and 20% in the ascending eptifibatide dose groups.
Major and minor bleeding increased with escalating dosages of eptifibatide (P<0·01). In this trial 97 bleeding events emerged on study treatment (including placebo), of which 50 were related to the catherization access site. No intracranial haemorrhage was observed (Table 2) .
Of all eptifibatide-treated patients, 15 patients received transfusions, five in each group (Table 2) . No patients on placebo needed transfusion (P=0·007). Patients receiving transfusions included one patient in the lowest dose group undergoing CABG, while all other transfusions were required for manifest bleeding or Hb decrease.
The core laboratory reported TIMI 3 flow at 90 min in 46, 42 and 45% of patients receiving ascending doses of eptifibatide. In the combined eptifibatide groups, TIMI 3 flow was more frequent than in the placebo group: 44 vs 31%, although not statistically significant, P=0·07 (Fig. 1) . Also patency defined as either TIMI 2 or TIMI 3 flow was more frequent with eptifibatide: 78% vs 61% with placebo, P=0·02 (Table 3) . No difference was observed between the three eptifibatide infusion regimens (Fig. 1) .
Re-occlusion was not noted in either the placebo or the lowest dose eptifibatide patients, but occurred in two and three patients in the other eptifibatide groups. TIMI 3 flow at day 7 revealed no significant differences between groups, ranging from 64% to 77%. Also patency rates (TIMI 2 or 3) were similar (Table 3) .
Left ventricular function was assessed by angiography in 145 patients, and could be quantified by the Cardialysis core laboratory in 79 patients. Ejection fractions were not different among the groups (Table 4) . Also, STsegment resolution patterns were similar. In placebo patients, 49% demonstrated complete ST-resolution, compared to 41, 38 and 55% for the escalating eptifibatide groups (Table 4) . Clinical outcome was not affected by combination therapy in this limited series of patients. In particular, death, recurrent infarction and percutaneous coronary intervention were not significantly different between groups (Table 5 ). Nine patients died before the end of follow-up. Four patients had been randomized to placebo, and 1, 2 and 2 in the respective eptifibatide groups. One placebo treated patient was lost to follow-up.
Discussion
A combination of fibrinolytic therapy (standard dose streptokinase) with ascending doses of the platelet glycoprotein IIb/IIIa receptor blocker, eptifibatide, did result in improved coronary perfusion as assessed by angiography. These results confirm studies with other fibrinolytic-IIb/IIIa receptor blocker combinations [24] . However, at 90 min angiography no differences in patency between eptifibatide groups were seen. In fact, the actual dose administered at 90 min was similar among the eptifibatide groups, since the bolus was relatively large: 180 g . kg 1 in all three groups. This represents the major part of the total infused volume at 90 min. ST-resolution measurements, often used as surrogate markers for tissue perfusion, failed to demonstrate significant differences between groups.
The combination of streptokinase and eptifibatide was not superior to coronary patency as achieved with alteplase [16] and other tissue plasminogen P-values are calculated with a chi-square-test for placebo and combined eptifibatide groups. n is the number of patients in whom two angiograms were available for analysis of re-occlusion.
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activators [25] [26] [27] , while bleeding rates and transfusion requirements in the current trial were excessive (Table  2) . Streptokinase is a non-fibrin specific thrombolytic and is therefore likely to interfere with normal haemostasis more than fibrin-specific agents, such as tPA and other plasminogen activators, which may explain the excess of bleeding in this study.
A strategy of full dose fibrinolytic (alteplase) combined with a platelet glycoprotein IIb/IIIa receptor blocker (eptifibatide) was also tested in IMPACT-AMI [15] . Patency improved significantly, with 66% TIMI 3 flow for eptifibatide (180 g . kg 1 bolus, 0·75 g . kg 1 . min 1 infusion) compared to 39% for the placebo group (P=0·006), while bleeding was not increased.
In the PARADIGM trial, the platelet GP IIb/IIIa receptor inhibitor lamifiban was given in adjunct to full dose streptokinase (without heparin) or to alteplase (with heparin) [28] . An increase in bleeding was reported in patients treated with lamifiban in combination with full dose streptokinase: 16·1% of lamifiban and 10·3% of placebo treated patients received transfusions.
A different strategy was followed in the GUSTO-IV pilot or SPEED trial presented at the 20 th European Congress of Cardiology in Vienna in 1998 and in the TIMI-14 trial [24] . In these trials, full dose platelet glycoprotein IIb/IIIa receptor blocker (abciximab) was tested in combination with a reduced dose of a fibrinolytic agent (respectively reteplase and alteplase). Data on a combination of full-dose abciximab with a reduced dose of 35 mg of alteplase infused in 60 min demonstrated an encouraging 77% TIMI 3 flow at 90 min, compared to 62% for full dose alteplase alone (P=0·02). In a small group of patients in this dose titration trial, abciximab with full dose streptokinase showed an unacceptable risk of bleeding complications and accordingly this regimen was not further investigated.
Throughout these trials a consistent improvement of TIMI 3 flow was achieved by a combination of fibrinolytic therapy and platelet glycoprotein IIb/IIIa receptor blockers. However, full dose fibrinolytic therapy with streptokinase and a platelet glycoprotein IIb/IIIa receptor blocker leads to an unacceptable bleeding risk. Due to this risk, and the fact that full dose streptokinase with a platelet glycoprotein IIb/IIIa receptor blocker results in TIMI 3 flow not superior to flow rates seen after standard tPA treatment, this treatment strategy seems not to be of clinical benefit. In contrast, a strategy combining a fibrinolytic agent in a reduced dose with a platelet glycoprotein IIb/IIIa receptor blocker at a level which inhibits over 80% of platelet aggregation, seems promising [24] . Large randomized trials with clinical end-points are needed to assess the clinical benefit which may be expected from improvement of early TIMI 3 Numbers of patients with each event throughout the 30-day follow-up.
flow rates in relation to the possible increased bleeding risk.
While waiting for such large trials, we recommend avoiding streptokinase in patients who develop myocardial infarction while receiving eptifibatide or another platelet glycoprotein IIb/IIIa receptor blocker, and to treat such patients by either direct PTCA or with a reduced dose of alteplase or reteplase.
